Lyell Immunopharma Inc (NASDAQ:LYEL) price on Thursday, February 06, fall -4.68% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.59.
A look at the stock’s price movement, the close in the last trading session was $0.62, moving within a range at $0.57 and $0.628. The beta value (5-Year monthly) was -0.483. Turning to its 52-week performance, $3.26 and $0.55 were the 52-week high and 52-week low respectively. Overall, LYEL moved -12.83% over the past month.
Lyell Immunopharma Inc’s market cap currently stands at around $172.67 million, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -100.00% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 53k, representing a -59.23% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LYEL is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 0 recommend LYEL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LYEL’s current price about -0.48% and -15.50% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.63, while 7-day volatility ratio is 7.31% and 7.83% in the 30-day chart. Further, Lyell Immunopharma Inc (LYEL) has a beta value of -0.37, and an average true range (ATR) of 0.05. Analysts have given the company’s stock an average 52-week price target of $1, forecast between a low of $1 and high of $1. Looking at the price targets, the low is -69.49% off current price level while to achieve the yearly target high, price needs to move -69.49%. Nonetheless, investors will most likely welcome a -69.49% jump to $1 which is the analysts’ median price.
If we refocus on Lyell Immunopharma Inc (NASDAQ:LYEL), historical trading data shows that trading volumes averaged 0.77 over the past 10 days and 1.16 million over the past 3 months. The company’s latest data on shares outstanding shows there are 256.56 million shares.
The 48.38% of Lyell Immunopharma Inc’s shares are in the hands of company insiders while institutional holders own 21.58% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 12.4 million on 2025-01-15, giving us a short ratio of 10.75. The data shows that as of 2025-01-15 short interest in Lyell Immunopharma Inc (LYEL) stood at 573.0 of shares outstanding, with shares short rising to 10.99 million registered in 2024-12-13. Current price change has pushed the stock -7.66% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LYEL stock continues to rise going into the next quarter.
